RPS6KB1 and melanoma: RAF and MEK inhibitor combination has been found to be less effective in BRAF-mutant melanoma tumours with MAPK-independent resistance in which ERK is adequately suppressed but alternatively mTOR is activated as estimated by the phosphorylation of p70S6 kinase 1 (S6K1)9.